Chinese Journal of Cancer Research

Papers
(The H4-Index of Chinese Journal of Cancer Research is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Efficacy and safety of low-dose cyclophosphamide combined with lenvatinib, pembrolizumab and TACE for unresectable hepatocellular carcinoma: A single-center, prospective, single-arm clinical trial67
Gastric cancer surgery in South Korea: Past, present, and future54
Transforming cancer cells for long-term living with cancer: An inspiring new approach47
Molecular features of gastroenteropancreatic neuroendocrine carcinoma: A comparative analysis with lung neuroendocrine carcinoma and digestive adenocarcinomas36
Pathogenic germline variants in mismatch repair genes in patients with microsatellite instability-high gastric cancer35
Focal ablation therapy presents promising results for selectively localized prostate cancer patients33
Efficacy of ctDNA methylation combined with traditional detection modality to detect liver cancer among high-risk patients: A multicenter diagnostic trial33
Clinical and molecular significance of homologous recombination deficiency positive non-small cell lung cancer in Chinese population: An integrated genomic and transcriptional analysis31
Heterogeneity of tumor-infiltrating myeloid cells in era of single-cell genomics28
Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumors27
National guidelines for diagnosis and treatment of thyroid cancer 2022 in China (English version)27
Updates of CSCO guidelines for colorectal cancer version 202527
Detection and classification of breast lesions using multiple information on contrast-enhanced mammography by a multiprocess deep-learning system: A multicenter study26
Mn-based cGAS-STING activation for tumor therapy26
Microbiota and urinary tumor immunity: Mechanisms, therapeutic implications, and future perspectives24
Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A19
Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China18
Multi-omics profile of exceptional long-term survivors of AJCC stage III triple-negative breast cancer17
0.019270181655884